Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bauer, T. W.
Right arrow Articles by Ellis, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauer, T. W.
Right arrow Articles by Ellis, L. M.
Mol Cancer Ther. 2006;5:1676-1682
© 2006 American Association for Cancer Research

Research Articles: Targets

Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells

Todd W. Bauer1, Ray J. Somcio2, Fan Fan2, Wenbiao Liu2, Marjorie Johnson2, Donald P. Lesslie2, Douglas B. Evans1, Gary E. Gallick2 and Lee M. Ellis1,2

Departments of 1 Surgical Oncology and 2 Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Lee M. Ellis, Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-6926; Fax: 713-792-4689; E-mail: lellis{at}mdanderson.org

Pancreatic carcinoma cells overexpress the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and the hepatocyte growth factor (HGF) receptor, c-Met, which are both known to mediate tumor cell migration and invasion. We hypothesized that IGF-IR and c-Met cooperate to induce migration and invasion of human pancreatic carcinoma cells and that IGF-I-mediated migration and invasion depend on c-Met. Migration and invasion assays were done with the human pancreatic cancer cell line L3.6pl treated with PBS, IGF-I, HGF, or IGF-I plus HGF. To determine if c-Met is necessary for IGF-IR-mediated migration and invasion, c-Met was down-regulated in L3.6pl cells via adenoviral infection with a c-Met ribozyme before IGF-I treatment. IGF-I and HGF increased cell migration and invasion. Furthermore, IGF-I plus HGF had a greater than additive effect on cell migration and invasion compared with either growth factor alone. Down-regulation of c-Met nearly completely inhibited IGF-I-mediated migration and invasion. Our findings suggest that IGF-IR and c-Met cooperate to induce migration and invasion of human pancreatic carcinoma cells. Furthermore, c-Met is required for both HGF- and IGF-I-mediated migration and invasion. Elucidation of the signaling pathways that contribute to tumor progression and metastasis should provide a foundation for the development of targeted therapies for pancreatic carcinoma. [Mol Cancer Ther 2006;5(7):1676–82]


Grant support: NIH T32 grant CA-09599 (T.W. Bauer), NIH Cancer Center Support grant CA-16672, and Lockton Fund for Pancreatic Cancer Research grant (D.B. Evans, G.E. Gallick, and L.M. Ellis).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/ 2/05; revised 4/21/06; accepted 5/ 4/06.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. A. Lang, P. Schachtschneider, C. Moser, A. Mori, C. Hackl, A. Gaumann, D. Batt, H. J. Schlitt, E. K. Geissler, and O. Stoeltzing
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Mol. Cancer Ther., November 1, 2008; 7(11): 3509 - 3518.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A.D. Carano, I. Kasman, E. Mai, J. Young, et al.
MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Cancer Res., June 1, 2008; 68(11): 4360 - 4368.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1471 - 1477.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Matsushita, T. Gotze, and M. Korc
Hepatocyte Growth Factor Mediated Cell Invasion in Pancreatic Cancer Cells Is Dependent on Neuropilin-1
Cancer Res., November 1, 2007; 67(21): 10309 - 10316.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Lang, C. Moser, A. Gaumann, D. Klein, G. Glockzin, F. C. Popp, M. H. Dahlke, P. Piso, H. J. Schlitt, E. K. Geissler, et al.
Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth
Clin. Cancer Res., November 1, 2007; 13(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.